Expert Interview
A Third View: Examining the treatment landscape and the potential of AstaZeneca's nirsevimab in light of the recent unanimous recommendation by the FDA advisory committee for prevention of RSV lower respiratory tract disease in infants.
Ticker(s): AZNInstitution: UC Davis
- Professor and Vice Chair for Research in the Department of Pediatrics at the UC Davis School of Medicine and Director of the Center for Health and Technology at UC Davis Health.
- Treats approximately 10 infants/children with RSV per shift
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
